Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Blood|June 9, 2025
Eliminating the need for sequential confirmation of response in multiple myelomaJean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, et al.American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.American Journal of Hematology|December 16, 2020
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myelomaJoselle Cook, Isla Johnson, Alexandra Higgins, et al.Leukemia Research|October 17, 2013
The clinical significance of cereblon expression in multiple myelomaSteven R Schuster, K Martin Kortuem, Yuan Xiao Zhu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2019
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice GuidelineJoseph Mikhael, Nofisat Ismaila, Matthew C Cheung, et al.Cancer Medicine|October 6, 2020
Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatmentIuliana Vaxman, Abdullah S Al Saleh, Shaji Kumar, et al.Blood|January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyPaul G Richardson, David S Siegel, Ravi Vij, et al.The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.Pageof 4